The hERG K+ channel: target and antitarget strategies in drug development
- 1 March 2008
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 57 (3) , 181-195
- https://doi.org/10.1016/j.phrs.2008.01.009
Abstract
No abstract availableKeywords
This publication has 148 references indexed in Scilit:
- Alfuzosin Delays Cardiac Repolarization by a Novel MechanismThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Coexistence of hERG current block and disruption of protein trafficking in ketoconazole‐induced long QT syndromeBritish Journal of Pharmacology, 2008
- Doxazosin induces apoptosis of cells expressing hERG K+ channelsEuropean Journal of Pharmacology, 2008
- Drug‐induced long QT syndrome: hERG K+channel block and disruption of protein trafficking by fluoxetine and norfluoxetineBritish Journal of Pharmacology, 2006
- Combined hERG channel inhibition and disruption of trafficking in drug‐induced long QT syndrome by fluoxetine: a case‐study in cardiac safety pharmacologyBritish Journal of Pharmacology, 2006
- Ether-a-go-go Related Gene Potassium Channels: What's All the Buzz About?Schizophrenia Bulletin, 2006
- Ether à go-go potassium channels and cancerCancer Letters, 2006
- HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycinCancer Chemotherapy and Pharmacology, 2005
- Mechanisms of Arsenic-Induced Prolongation of Cardiac RepolarizationMolecular Pharmacology, 2004
- Relations of QTc prolongation on the electrocardiogram to torsades de pointes: Definitions and mechanismsThe American Journal of Cardiology, 1993